Clinical Trials Directory

Trials / Completed

CompletedNCT00997893

Research Investigation of Soy and Estrogen

Effects of Estradiol and Soy on Menopausal Symptoms

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
96 (actual)
Sponsor
University of Illinois at Chicago · Academic / Other
Sex
Female
Age
40 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.

Detailed description

Anxiety is a common, but understudied complaint in midlife women, and increases during the menopausal transition. Changes in estrogen are dramatic during the menopausal transition, and indirect data suggest a potential role for estrogen, particularly estrogen receptor beta, in mediating anxiety. Two subtypes of the estrogen receptor, alpha and beta (ER-alpha and ER-beta), appear to be critically involved in the expression of anxiety in females. Compounds that preferentially target ER-beta, including plant-derived estrogens (phytoestrogens), lower both anxiety behaviors and responsivity to discrete stressors, including social stress, in laboratory animals. The primary aim of this proposal is to carry out the first study to translate these preclinical studies to humans by comparing and contrasting of the effects of phytoestrogens, estradiol, and placebo on daily anxiety and responses to moderate psychosocial stress in the laboratory. As second focus is emotional and non-emotional cognition. This focus stems from evidence that estrogen can protect against the negative impact of glucocorticoids on memory. These aims will be accomplished in a 12-week randomized placebo-controlled, clinical trial comparing three treatments: 1) a phytoestrogen supplement (Novasoy® 400, 55 mg tablet twice daily); 2) oral estradiol (1 mg/daily; plus 10 mg medroxyprogesterone acetate at study end 10 for 10 days); and 3) placebo (identical appearing tablets twice daily). The enrollment target is 120 healthy women in the menopausal transition (40 per group). To measure anxiety, women will complete the State-Trait Anxiety Inventory (STAI). To measure responsivity to psychosocial stress, parallel forms of the Trier Social Stress Test, a widely used laboratory induction that involves unanticipated public speaking and social evaluative fear, will be used to induce moderate psychosocial stress before and after treatment. At both laboratory sessions, measures of subjective stress (STAI), cortisol, and emotional memory performance will be obtained at multiple points during a control condition and during the psychosocial stress condition. Lastly, we will measure treatment effects on measures of verbal memory.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSoy PhytoestrogenNovasoy® pill (55 mg)
DRUGEstradiolEstradiol pill (1 mg)
DRUGMedroxyprogesterone Acetate (MPA)medroxyprogesterone acetate (MPA) (10mg)
DRUGSoy Placebooral placebo pill (0mg Soy Phytoestrogen)
DRUGMPA Placebooral placebo pill (0mg MPA)

Timeline

Start date
2009-12-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2009-10-19
Last updated
2020-12-07
Results posted
2020-12-07

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT00997893. Inclusion in this directory is not an endorsement.